Global Age-Related Macular Degeneration (AMD) Market Trends and 2018 Opportunities

The report titled “Global Age-Related Macular Degeneration (AMD) Market: Trends & Opportunities (2013-2018)” provides an in-depth analysis of the global age-related macular degeneration market with detailed analysis of various countries like the United States, U.K, Australia. It also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall AMD market has also been forecasted for the period 2013-2018, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Norvatis, Regeneron, Roche and Bayer are profiled.

Regional Coverage

 U.S
 U.K
 Australia

Company Coverage

 Norvatis
 Regeneron
 Roche
 Bayer  

Place a direct purchase order of this research report @

Age-related macular degeneration (AMD) is a condition affecting older people, and involves the loss of the person's central field of vision. Several forms of AMD exist such as early AMD, late AMD, dry AMD, Wet AMD etc. Globally, the disease ranks third as a cause of blindness after cataract and glaucoma. The main factor is ageing and other risk factors may include the use of tobacco, genetic tendencies, the degree of pigmentation (with light colored eyes being at higher risk), arterial hypertension, the ultraviolet rays, and consumption of a non-balanced diet. As for the cure of the disease, there is at present no definitive treatment. Palliative treatments which are able to retard the progress of the disease include the use of intravitreous drugs or injections, lasers, dynamic phototherapy and sometimes surgery.

Globally the prevalence of AMD disease is highest in the U.S followed by the U.K and Australia. The world’s elderly population is the fastest growing age group; this is the main reason for the rising prevalence of AMD. Rising smoking habit, and unhealthy diet are the other reasons which will increase the count of AMD affected people in the near future. New types of drugs such as Eylea have come up which is indicated for the treatment of patients with neovascular (wet) age related macular degeneration and expected to substitute Lucentis and Avastin drugs in the coming years.

Complete report available @

Table of Contents

1. Executive Summary 

2. Age-Related Macular Degeneration (AMD): An Introduction

2.1 Sign and Symptoms of AMD 
2.2 Causes and Risk Factors of AMD 
2.3 Diagnosis of AMD 
2.4 Treatment of AMD 
2.4.1 Treatment of Wet AMD 
2.4.2 Treatment of Dry AMD 

3. Global Age-Related Macular Degeneration Market: Analysis and Forecast 

3.1 Global AMD Market: Sizing and Growth 
3.1.1 Global AMD Market Size by Value: Actual and Forecast 
3.1.2 Global AMD Market Size by Volume: Actual and Forecast 
3.2 Global Market Share of AMD 
3.2.1 AMD Market Share by Type 
3.2.2 AMD Market Share by Country 
3.2.3 Common Causes of Blindness- Percentage Share 
3.2.4 Common Causes of Visual Impairment- Percentage Share
3.3 Worldwide Prevalence of AMD 
3.3.1Prevalence of AMD by Stages 
3.3.2 Prevalence of AMD by Type 
3.3.3 Prevalence of AMD by Visual Impairment 

4. Australia - Age Related Macular Degeneration Market: Analysis and Forecast 

4.1 Australian AMD Market: Sizing and Growth
4.2 Prevalence of AMD in Australia 
4.2.1 Prevalence of AMD Compared to Other Diseases 
4.2.2 Prevalence of AMD by Age 
4.3 Causes of Blindness in Australia 

5. The U.S - Age Related Macular Degeneration Market: Analysis and Forecast 

5.1 The US AMD Market: Sizing and Growth
5.2 Prevalence of AMD in the US
5.1.1 Prevalence of AMD by Race 
5.1.2 Prevalence of AMD by Gender 

6. The U.K - Age Related Macular Degeneration Market: Analysis and Forecast 

6.1 The UK AMD Market: Sizing and Growth
6.2 Market Sizing and Forecast by Gender 
6.3 Prevalence of AMD in the UK 
6.3.1 Late AMD 
6.3.2 Dry AMD 
6.3.3 Wet AMD 

7. Global AMD Market: Competitive Landscape 

8. Market Dynamics: Global AMD Market 

8.1 Growth Drivers 
8.2 Challenges 
8.3 Market Trends 
8.3.1 Radiation Therapy Treatment for AMD 
8.3.2 New Drugs Eylea for the Treatment of AMD 

9. Company Profiles: Global AMD Market 

9.1 Norvatis 
9.1.1 Business Overview 
9.1.2 Financial Overview 
9.1.3 Business Strategy 

9.2 Regeneron
9.2.1 Business Overview 
9.2.2 Financial Overview 
9.2.3 Business Strategy 

9.3 Roche 
9.3.1 Business Overview 
9.3.2 Financial Overview 
9.3.3 Business Strategy 

9.4 Bayer 
9.4.1 Business overview 
9.4.2 Financial Overview 
9.4.3 Business Strategy 

List of Figures